Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
Clinical trial NCT03177239 · UNKNOWN
Trial details
- NCT number
- NCT03177239
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-19
- Primary completion
- 2021-12-31
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.